Melbourn Scientific Opens EU Market with Inhaler Test Service

Import testing for companies wanting to access European markets is just one of the services being offered by Melbourn Scientific at Inhalation Asia, Hong Kong (26-28 June).

With over 20 years of experience in analytical testing and formulation for inhaled products, the company is now said to offer one of largest teams in Europe offering contract research for OINDP development, product development and associated CMC services. These include formulation development, analysis, stability studies, inhaler testing and small scale manufacture of clinical trials materials.

Melbourn Scientific has been audited by the MRHA and FDA and was recently awarded a Manufacturer's/Importer’s Authorisation (MIA) allowing it to be named as an EU testing and release site.

CEO Mark Hammond said the new licence is a good endorsement of the quality of the company’s cGMP procedures and extends its capabilities: “The EU is an important market and with the Manufacturer’s / Importer’s Authorisation (MIA), we are able to import commercial products which have been manufactured outside the EU and to test them prior to release for sale within the EU/EEA. This has extended our portfolio of services for international clients.*

Hammond continued ‘We are seeing an increase in interest from companies across Asia and India who are looking for CRO partners with proven expertise in supporting inhaled and intranasal programs. Inhalation Asia will be the first time we have exhibited in the Far East and we are looking forward to the experience."